Next Phase Newsletter

A newly established venture capital firm founded in 2020 and is based in Barcelona, Spain. The firm is currently raising its first fund targeting €30M, and expects to close in mid to late 2021 and become fully operative. The firm is actively seeking investment opportunities and performing due diligence on companies they identify as a fit with the firm. The firm’s focus is in Seed to Series A financings and initial size of investment will be around €500K, and can invest up to €2.5M over the life of investment. While the firm is open to USA-based opportunities, they will focus on those based in Europe, Israel, and Spain where the firm is based.

The firm is exclusively interested in companies in the longevity space. In this regard, the firm is most interested in digital technologies including AI, robotics, data analytics, etc. Traditional therapeutics or devices do not fall within their investment priority, as the firm prefers to seek opportunities that leverage digital technologies to deliver novel therapeutic solutions (i.e. digital therapeutics). The firm is open to very early-stage, pre-revenue technologies and are open to university spin-offs/tech transfers.

The firm is backed by co-founders who have entrepreneurial backgrounds and can be a hands-on investor, assisting with company creation and other support as needed. When investing in companies that are not in geographical proximity to the firm, the firm prefers to co-invest alongside larger VC firms.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A family office founded in 2009 and based in Toronto, Ontario is now looking to expand into the healthcare sector. The group plans to initially invest approximately $10M into seed-stage deals in the healthcare space and may potentially reserve another pool of capital for additional healthcare investments in the future. The group has flexibility with deal structures and may make either straight equity or convertible loan investments depending on the deal. In addition to capital, the group looks to add value to portfolio companies through marketing and sales expertise. The firm has no specific number of healthcare investments it’s looking to make.

Within healthcare, the group is focused on the medtech, diagnostic and health IT space. The group is particularly interested in newly created or accessible markets such as leveraging smartphones, big data/data mining and AI for healthcare purposes. The group is highly interested in mobile diagnostic devices, diagnostics for the consumer market and portable lab devices. The firm will also look at more traditional FDA regulated medical devices and diagnostics on a secondary basis.

The group seeks companies addressing specific markets, but has no set requirements for entrepreneurs/management teams other than a very focused team that is passionate about the tech and market being pursued. The group typically seeks a board seat along with in an investment, but may not require one depending on the terms of the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A large designer, developer and manufacturer of drug delivery systems is active in R&D, design and manufacturing in all areas of healthcare. The firm is capable of a variety of deal structures, but prefers to enter into joint ventures and strategic partnerships as the firm seeks to be a value-added investor providing their expertise and capabilities in design and manufacturing as well as the resources of a large company while allowing the entrepreneur to drive the development of the technology.

The firm’s expertise lies in drug delivery devices, but has capabilities and is highly interested in all areas of medical technology/devices, biosensors and wearables, B2B or B2C healthcare IT applications including data analytics and cloud computing as well as robotics and AI as it applies to surgery prosthetics, rehabilitation and drug discovery. The firm has a particular interest in the diabetes space and has done work in this area in the past.

The firm is open to working with all entrepreneurs and is open to companies on a global basis. The firm does look for a board seat along with an investment, but strives to not be restrictive in any way and let the management team run the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Founded in 2014, a venture capital firm specializes in life sciences and medical technology, managing both RMB and USD funds with a total size of $600M. The firm is located in Beijing, China, operated by a professional team with diversified and profound industry backgrounds, having made over 40 investments with high growth potential since 2014. For the firm’s RMB fund, the typical allocation size is 30M-50M RMB, and can go up to 200M RMB. For the USD fund, the firm invests $5M USD on average and can go up to $20M USD.

The firm is open to investing in general Bio-medical industries globally, including diagnostics, medical devices, therapeutics and AI in the healthcare service platform. The firm is especially interested in medical imaging, minimally invasive diagnosis specially IVD and treatment, diagnostic reagents and mobile health. The firm prefers diagnostics companies that are at the growth stage but are looking for biotech companies in the seed stage. It’s not interested in small molecules nor antibodies for now.

The firm prefers companies with China Angle, focusing on promising pioneers that operate in healthcare subsegments with lower regulatory risks and introduce global technology into the Chinese market.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A life sciences venture capital firm based in USA is focused on early and growth-stage biotech and pharma companies. The group has $300M assets under management and recently closed its third fund. Initial investments typically are in the $3M-$8M range and are usually in the form of equity, but may use convertible notes in select situations. The firm look to take meaningful stake in portfolio companies and play an active role in their development. The firm is open to companies based in the U.S., with a specific interest in companies located outside of the major biotech hubs of Boston and San Francisco.

The firm is most interested in the biotech/therapeutics space. The firm does not invest in diagnostic or healthcare IT companies. The firm is mostly opportunistic in terms of technology type and indication area; however, the group prioritizes companies with products addressing unmet medical needs and unique mechanisms of action. Bios typically invests in companies ranging from late preclinical to Ph. II clinical trials.

The firm has no strict company or management team requirements, but does look to be a very active investor and always requires a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Western Europe is looking to make 4-5 investments over the next 6 to 12 months. could lead any investment up to €15M but will also look for syndicate participation in bigger rounds. Allocations are in the form of equity. Allocations are typically made at the venture stage of development but are open to consider Seed through IPO rounds. The firm focuses on companies based in Europe, but also considers companies in Israel and USA.

The firm will look at a broad spectrum of products and services within the life science space. While the firm has traditionally not considered therapeutics, the firm is now open to making investments in this space. The firm is most interested in medical devices and diagnostics including in-vitro diagnostics, and also looks into digital health. They will look at any stage of development within those categories and long as the product or service shows substantial market potential and have proof of concept.

The firm is willing to work with all types of management teams as long as entrepreneurs/founders have a solid knowledge in the industry. A board seat is required for all investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm based in the USA just successfully closed the first round of their fund The firm invests globally in medically related early-stage companies. Initial size of investment ranges from $250 – 500K. While the firm is focused on USA-based companies, the firm is open to considering companies across the globe.

The firm invests in medtech and digital health companies. Regarding specific types of technologies, the firm is generally opportunistic and will consider any promising technologies that address unmet medical need. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology.

The firm has no specific company or management team requirements, and is open to acting as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.